β-catenin signaling: Therapeutic strategies in oncology

Cancer Biology and Therapy

Volumn 1, Issue 6, 2002, Pages 621-625

  Li, Han ^a   Pamukcu, Rifat ^a   Thompson, W Joseph ^a  

^a Cell Pathways Inc   (United States)

Author keywords

Apoptosis; cGMP; Colon cancer; Cyclin D1; Exisulind; GSk3 ; PDE; Protein kinase G; SAANDs; catenin

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; AXIN PROTEIN; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; DRUG DERIVATIVE; PROTEIN; REPRESSOR PROTEIN; SULINDAC; SULINDAC SULFONE; TRANSACTIVATOR PROTEIN;

ANIMAL; COLON POLYPOSIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; ONCOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ADENOMATOUS POLYPOSIS COLI; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CYTOSKELETAL PROTEINS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SULINDAC; TRANS-ACTIVATORS;

EID: 0038243190     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.309     Document Type: Review

References (60)

1. Behrens J. Control of beta-catenin signaling in tumor development. Ann NY Acad Sci 2000; 910:21-33.
2. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 2000; 287:1606-9. (Pubitemid 30127755)
3. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of beta- catenin. J Biol Chem 1997; 272:24735-8. (Pubitemid 27415637)
4. Laney JD, Hochstrasser M. Substrate targeting in the ubiquitin system. Cell 1999; 97:427-30. (Pubitemid 29231165)
5. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben Shushan E, Mann M, et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 2002; 16:1066-76. (Pubitemid 34507196)
6. Hagen T, Vidal-Puig A. Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. Biochem Biophys Res Commun 2002; 294:324-8. (Pubitemid 34694097)
7. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108:837-47. (Pubitemid 34327534)
8. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996; 272:1023-6. (Pubitemid 26259322)
9. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70. (Pubitemid 26358996)
10. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 1995; 92:4482-86.
11. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P. Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 2001; 153:555-68. (Pubitemid 34280142)
12. Miyoshi K, Shillingford JM, Le Provost F, Gounari F, Bronson R, von Boehmer H, et al. Activation of beta -catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci USA 2002; 99:219-24. (Pubitemid 34060344)
13. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000; 45:323-34.
14. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002; 21:2679-94.
15. de La CA, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95:8847-51. (Pubitemid 28350577)
16. Gamallo C, Palacios J, Moreno G, Calvo dM, Suarez A, Armas A. beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999; 155:527-36. (Pubitemid 29370402)
17. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih I, Buhler K et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002; 34:9-16. (Pubitemid 34260591)
18. Iwao K, Miyoshi Y, Nawa G, Yoshikawa H, Ochi T, Nakamura Y. Frequent beta-catenin abnormalities in bone and soft-tissue tumors. Jpn J Cancer Res 1999; 90:205-9. (Pubitemid 29112321)
19. Omholt K, Platz A, Ringborg U, Hansson J. Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 2001; 92:839-42. (Pubitemid 32467373)
20. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999; 154:325-9. (Pubitemid 29094082)
21. Rubinfeld B, Robbins P, El Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275:1790-2. (Pubitemid 27136716)
22. Saegusa M, Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001; 194:59-67.
23. Sommers CL, Gelmann EP, Kemler R, Cowin P, Byers SW. Alterations in beta-catenin phosphorylation and plakoglobin expression in human breast cancer cells. Cancer Res 1994; 54:3544-52.
24. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J. Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 2001; 30:316-21.
25. Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60:4709-13.
26. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58:2520-3. (Pubitemid 28275418)
27. Webster MT, Rozycka M, Sara E, Davis E, Smalley M, Young N et al. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 2000; 28:443-53. (Pubitemid 30451797)
28. Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, Kolligs FT et al. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 2002; 160:1229-38. (Pubitemid 34411627)
29. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 2001; 3:793-801. (Pubitemid 32842684)
30. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta 1999; 1424:M23-37.
31. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote Beta -catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 2002; 277:17933-43. (Pubitemid 34967604)
32. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, et al. Liganded Androgen Receptor Interaction with beta -Catenin. Nuclear co-localization and modulation of transcriptional activity in neuroal cells. J Biol Chem 2002; 277:20702-10. (Pubitemid 34967374)
33. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787-90. (Pubitemid 27136715)
34. Shih IM, Yu J, He TC, Vogelstein B, Kinzler KW. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000; 60:1671-6. (Pubitemid 30183440)
35. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999; 59:4634-41.
36. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell 1999; 99:335-45. (Pubitemid 29519912)
37. Li H, Liu L, David M, Whitehead CM, Chen M, Fetter J, et al. Pro-apoptotic Actions of Exisulind and CP461 in SW480 Colon Tumor Cells Involve b-Catenin and Cyclin D1 Down Regulation . Biochem Pharmacol 2002; 64:1325-36. (Pubitemid 35248250)
38. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000; 60:3338-42. (Pubitemid 30482142)
39. Thompson WJ, Liu L, Li H, Fetter J, Sperl G, Piazza G, et al. Exisulind Induces apoptosis in colonic tumor cells lacking APC mutations by cyclic GMP mediated beta-catenin reduction. Gastroenterology 2000; 118:A670.
40. Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 1999; 53:440-5. (Pubitemid 29063347)
41. Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 1999; 470:45-53.
42. Ahnen DJ. Colon cancer prevention by NSAIDs: what is the mechanism of action? Eur J Surg Suppl 1998;:111-4.
43. Alberts DS, Hixson L, Ahnen D, Bogert C, Einspahr J, Paranka N, et al. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl 1995; 22:18-23.
44. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-16. (Pubitemid 23131373)
45. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993; 88:1652-6. (Pubitemid 23298112)
46. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997; 57:2452-9. (Pubitemid 27255906)
47. Bunn PA, Jr., Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, et al. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol 2002; 29(1 Suppl 4):87-94. (Pubitemid 34226523)
48. Han EK, Arber N, Yamamoto H, Lim JT, Delohery T, Pamukcu R, et al. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 1998; 48:195-203. (Pubitemid 28159947)
49. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999; 58(7):1097-1107. (Pubitemid 29381510)
50. Malkinson AM, Koski KM, Dwyer-Nield LD, Rice PL, Rioux N, Castonguay A et al. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis 1998; 19(8):1353-1356.
51. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001; 61(10):3961-3968. (Pubitemid 32720958)
52. Soh JW, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem 2001; 276(19):16406-16410.
53. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997; 57(2):267-271. (Pubitemid 27036604)
54. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57(14):2909-2915. (Pubitemid 27315038)
55. Arber D, Rex D, Sjodahl R, Hultcrantz R, Kuwada S. Exisulind Induced Regression of Sporadic Adenomatous Polyps in a Randomized, Double-Blind, Placebo Controlled Trial . DDW Abstract 2002 2002; 11(#104807).
56. Burke C, Stolk R, Arber N, Hultcrantz R, Bjork J, Syngal S, et al. Exisulind Prevents Adenoma Formation in Familial Adenomatous Polyposis (FAP). Gastroenterology 2000; 118(4):3604.
57. Phillips RK, Hultcrantz R, Bjork J, Beveridge I, Arber N, Syngal S, et al. Exisulind,a Pro-apoptotic Drug, Prevents New Polyp Formation in Patients with Familial Adenomatous Polyposis. Gut 2000; 47(3):A2-3.
58. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, et al. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 2002; 8:904-12. (Pubitemid 34742124)
59. Liu L, Li H, Underwood T, Lloyd M, David M, Sperl G, et al. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther 2001; 299:583-92. (Pubitemid 32979671)
60. Li H, David M, Chen M, Liu L, Underwood T, Alila L, et al. Exisulind and CP461 Down-regulate Activated Wnt signaling in Colon Cancer Cells by Direct PKG, But not GSK3b, Phosphorylation of b-Catenin. Proc AACR 2002; 43(#2993).